10:05 AM EST - Appili Therapeutics Inc. : And its partner Vitalex Biosciences today announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded up to US$40 million in funding to support the development of VXV-01, a vaccine aimed at protecting against invasive fungal infections. Appili Therapeutics Inc.
shares T.APLI are trading up $0.02 at $0.03.
